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Letters
Will Avilamycin Convert
Ziracine into Zerocine?
To the Editor: Avilamycin and evernimicin
(Ziracine), which belong to the everninomicin
class of drugs, are oligosaccharide antibiotics
active against numerous gram-positive bacteria,
including emerging pathogens such as glycopep-
tide-resistant enterococci, methicillin-resistant
staphylococci, and penicillin-resistant pneumo-
cocci (1,2). The two drugs share the same mode
of action—inhibition of translation—by binding
to the same target in the large 50S ribosomal
subunit (3). As a result, they also display cross-
resistance: bacteria resistant to avilamycin are
resistant to evernimicin (and vice versa), but
not to other classes of drugs (4). Two mecha-
nisms of resistance to this class of drugs are
amino-acid substitution in ribosomal protein
L16 (5) and mutations in the peptidyltrans-
ferase domain of 23S ribosomal RNA (6).
Avilamycin has been used in Europe for
several years as a growth promoter for food
animals, particularly pigs. Enterococci resistant
to everninomycins have been isolated from
animals receiving avilamycin as a food addi-
tive (4). Evernimicin is being evaluated as a
human therapeutic agent. Indirect evidence
indicates that the use as growth promoters of
antibiotics that display cross-resistance with
those used in human therapy contributes to
antibiotic resistance in bacteria responsible for
human infections (7). As early as 1969, a
recommendation was published in the United
Kingdom that antibiotics used to treat infec-
tions in humans not be used as animal food
additives (8). In 1999, four antibiotics were
banned as food additives in the European
community.
Antibiotic resistance in human pathogens
has become a major health issue, complicated
by the fact that no new class of drugs has been
introduced for human therapy in the last 25
years. Since the use of avilamycin in animals
has favored selection of enterococcal strains
that are cross-resistant to evernimicin (4), these
bacteria can colonize the human gut or form a
pool of resistance genes that can spread to
human commensals or pathogens (9). The
continued use of avilamycin as a growth pro-
moter is likely to diminish the effectiveness of
evernimicin if Ziracine or any member of the
class is used for human therapy. Since
everninomicins will be prescribed mainly for
infections due to multiresistant gram-positive
cocci, avilamycin should be prospectively
banned as an animal growth promoter.
Patrice Courvalin
Institut Pasteur, Paris, France
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